Remove Pharmacokinetics Remove Research Laboratories Remove Virus
article thumbnail

Optimizing your ELISA Assays | BMG LABTECH

BMG Labtech

1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971. ELISAs played a pivotal role in the early detection of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).

Vaccine 98
article thumbnail

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

article thumbnail

Codon Digest: Injected Gene Editors

Codon

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Nature Neuroscience. Read You love to see it! Ricciardi M.J.

DNA 52
article thumbnail

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.